Investment Advisor, Upslope Capital Management

Upslope Capital Management

Investment Advisor

Investment advisor for Upslope Partners Fund, LP, a global long/short equity hedge fund.

Equity Bottom-Up

<ul><li>Q1 was challenging. However, in the two weeks since Mar 31, the world has changed, owing to an intense realignment of global trade policies.</li><li>This has swiftly aligned markets more with Upslope’s portfolio and approach.</li><li>April-to-date performance1 has been strong (approx. +7%), leaving the Fund +2% YTD (vs. -12% for the S&amp;P Midcap 400).</li></ul>

Q1 was challenging. However, in the two weeks since Mar 31, the world has changed, owing to an intense realignment of global trade policies.This has swiftly aligned markets more with Upslope’s portfolio and approach.April-to-date performance1 has been strong (approx. +7%), leaving the Fund +2% YTD (vs. -12% for the S&amp;P Midcap 400).

Upslope's Quarterly Investor Letter: 2025-Q1

<ul><li>Q4 was the most challenging quarter for Upslope since early 2021 (peak of the SPAC/meme stock bubble).</li><li>Longs underperformed and shorts dragged. Month-to-date performance has been similarly challenging (approximately -4% as of this writing).</li><li>In addition to a tough market environment, I made mistakes that made things worse.</li></ul>

Q4 was the most challenging quarter for Upslope since early 2021 (peak of the SPAC/meme stock bubble).Longs underperformed and shorts dragged. Month-to-date performance has been similarly challenging (approximately -4% as of this writing).In addition to a tough market environment, I made mistakes that made things worse.

Upslope's Quarterly Investor Letter: Q4 2024

United States

Charles River Laboratories International, Inc. provides research tools and support services that enable drug discovery and development.  The Company provides the animal research models required in research and development for new drugs, devices, and therapies.  Charles River's customers include pharmaceutical and biotechnology companies, hospitals, and academic institutions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Charles River Laboratories (CRL US)

Upslope's Quarterly Investor Letter: 2025-Q1

Q1 was challenging. However, in the two weeks since Mar 31, the world has changed, owing to an intense realignment of global trade policies.

Upslope Capital Management

Upslope's Quarterly Investor Letter: Q4 2024

Q4 was the most challenging quarter for Upslope since early 2021 (peak of the SPAC/meme stock bubble). Longs underperformed and shorts dragged.

Upslope Capital Management

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)